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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of rehabilitation therapies for people with CIP and CIM.
The primary objective is to assess the effectiveness of such interventions in improving daily activities such as walking, bathing, dressing
and eating.
Secondary objectives are to assess effects on muscle strength and quality of life, and to assess adverse effects of rehabilitation.
B A C K G R O U N D
Description of the condition
Critical illness myopathy (CIM) and polyneuropathy (CIP) are
common complications of critical illness that frequently occur
together. Both conditions cause weakness of limb and respiratory
muscles, which increase morbidity and impede recovery.
CIPisadistalaxonalsensory-motorpolyneuropathy,whichmeans
that multiple nerves that control movement and carry sensation
are affected. CIP presents as limb and respiratory muscle weak-
ness (Fan 2012; Lacomis 2000), and is closely associated with a
failure to wean patients from mechanical ventilation (Fan 2012;
Latronico 2011). The diagnostic criteria for CIP as a dysfunction
of (multiple) peripheral nerves are, according to Bolton 2005 and
Latronico 2011, as follows.
1. The individual is critically ill (multi-organ dysfunction and
failures).
2. The individual has limb weakness, or is difﬁcult to wean
from a ventilator (after exclusion of non-neuromuscular causes
such as heart and lung disease).
3. There is electrophysiological evidence of axonal motor and
sensory polyneuropathy.
4. There is an absence of a decremental response on repetitive
nerve stimulation (Latronico 2011).
A deﬁnite diagnosis of CIP, according to Bolton 2005 and
Latronico 2011, is established if all four criteria are fulﬁlled. A
probable diagnosis of CIP is established if criteria one, three and
1 Physical rehabilitation for critical illness myopathy and neuropathy (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.four are fulﬁlled.
CIM is a primary myopathy (that is, a muscle disorder) that is
notsecondary tomuscledenervation, andwhichhascharacteristic
electrophysiologicalandmorphologicalchanges(Latronico 2011).
The diagnostic criteria for critical illness myopathy are, according
to Latronico 2011, as follows.
1. The individual is critically ill (multi-organ dysfunction and
failures).
2. The individual has limb weakness, or is difﬁcult to wean
from a ventilator (after exclusion of non-neuromuscular causes
such as heart and lung disease).
3. Compound muscle action potential (CMAP) amplitudes
less than 80% of the lower limit of normal are recorded in two or
more nerves without conduction block.
4. Sensory nerve action potential amplitudes are more than
80% of the lower limit of normal.
5. Needle electromyography has detected:
i) short duration, low-amplitude motor unit potentials
with early or normal full recruitment, with or without
ﬁbrillation potentials in conscious and cooperative patients; or
ii) increased CMAP duration or reduced muscle
membrane excitability on direct muscle stimulation in non-
cooperative patients.
6. An absence of a decreasing response on repetitive nerve
stimulation.
7. Muscle histopathological ﬁndings of primary myopathy (for
example, myosin loss or muscle necrosis).
Fulﬁllment of all criteria establishes a deﬁnite diagnosis of CIM
(Latronico2011).Fulﬁllmentofcriteriaoneandthreetosixestab-
lishes a probable diagnosis of CIM. For our review we will apply
these deﬁnitions of CIP and CIM.
The pathophysiology of CIP and CIM is complex and remains
unclear (Hermans 2008). The development of CIP and CIM is
thought to involve electrical, microvascular, metabolic and bioen-
ergetic pathophysiological mechanisms (see Hermans 2008 for a
good overview). Crucial risk factors for CIP and CIM are sepsis,
systemic inﬂammatory response syndrome, and multiple organ
failure (Hermans 2008).
Exact numbers and rates of CIP and CIM are not well established
because of variations in the patient population, in risk factors and
in the diagnostic and assessment criteria used. In people receiv-
ing mechanical ventilation or with an increased risk of developing
multi-organ failure, the risk of developing CIP or CIM is about
30% and the risk increases up to 50% in people with acute respi-
ratory distress syndrome (Hermans 2008). The risk of developing
CIP or CIM is associated with a lengthy (more than one week)
stay in the intensive care unit (ICU), multi-organ failure (with
or without sepsis) and systemic inﬂammatory response syndrome
(Bercker 2005; Hermans 2008). A systematic review estimated
the incidence of CIP and CIM at 46% (95% CI 43% to 49%)
among adults who had remained in the ICU for more than two
weeks, who were receiving mechanical ventilation and had sepsis
or multi-organ failure (Stevens 2007).
The short- and long-term impact of CIP and CIM are well de-
scribed(Herridge2011;Ohtake2012;Hermans2008).Themus-
cleweaknessassociatedwiththeseconditionscanprolongtheneed
for supported ventilation and delay weaning from a ventilator. In
turn, this can mean a longer stay in the ICU and in hospital, and
slower rehabilitation (Hermans2008; Zanni 2010). Although full
recovery has been reported in approximately 50% of people with
CIM/CIP, improvementis relatedto theseverity of the condition.
People who are only mildly affectedcan recover within weeks, but
those with more severe weakness may take months to improve, or
in some cases, remain severely affected with partial or no recov-
ery (Hermans 2008). Clinical and neurophysiological signs may
remain for up to ﬁve years after discharge from hospital and may
lead to long-term paresis or paralysis (Herridge 2011).
Generalised weakness syndromes such as CIP and CIM are a ma-
jor cause of chronically impaired motor function that can affect
activities of daily living and participation. Physical rehabilitation
of those affected is therefore of great importance and interest.
Description of the intervention
Inthelastﬁveyears,researchhassuggestedthatphysicalrehabilita-
tionmayimproveactivitiesinpeoplewithCIPandCIM(Norton-
Craft 2012; Connolly 2012; Ohtake 2012; Bemis-Dougherty
2012; Fan 2012). Rehabilitation interventions include physical
and occupational therapy techniques, such as stretching, strength
training and mobility training (for example, training in dress-
ing and transfers, or to improve balance, sit-to-stand, and walk-
ing) (Burtin 2009; Hanekom 2011; Herridge 2011; Fan 2012;
Norton-Craft 2012). There has, however, been no Cochrane re-
view of the available literature on the efﬁcacy and acceptability of
physical rehabilitation approaches to treat people who have devel-
oped CIP and CIM.
Why it is important to do this review
Advances in medical care, increased survival rates and better di-
agnosis of CIP and CIM, as well as the availability of more effec-
tive therapy, have highlighted the need for and potential value of
rehabilitation for people with critical illness. However, although
rehabilitation guidelines give recommendations, there is limited
evidence on which to base practice (Connolly 2012). People with
ICU-acquired weakness may be most likely to beneﬁt from ongo-
ing rehabilitation (Connolly 2012). A recent special issue in the
journal Physical Therapy underlined the importance of the topic;
the authors concluded that physical rehabilitation approaches for
improving activities after CIP/CIM showedsome promising signs
ofeffectiveness(Bemis-Dougherty2012;Norton-Craft2012),but
there was a need for more evidence to provide clear guidelines.
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general is beneﬁcial, it is still unclear which speciﬁc rehabilitation
approaches are effective, and the most appropriate frequency and
intensity with which to apply them in practice (Connolly 2012).
There is currently no Cochrane systematic review in this area. We
thereforeaim,inthisCochranereview,tocompileandassessallthe
available literature about the effectiveness and safety of physical
rehabilitation in CIP and CIM, so as to provide comprehensive,
up-to-date evidence on which to base clinical practice.
O B J E C T I V E S
Toassesstheeffectsof rehabilitation therapiesforpeoplewithCIP
and CIM.
The primary objective is to assess the effectiveness of such inter-
ventions in improving daily activities such as walking, bathing,
dressing and eating.
Secondary objectives are to assess effects on muscle strength and
quality of life, and to assess adverse effects of rehabilitation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewillconsiderrandomisedcontrolledtrials(RCTs),quasi-RCTs
and randomised controlledcross-over trials. Quasi-RCTs are trials
in which themethod usedto allocate participants to interventions
is not truly random (for example, using date of birth or hospital
number).
Types of participants
We will include participants aged 18 and over in both inpatient
and outpatient settings, who have generalised weakness syndrome
andaconﬁrmedor probable diagnosis ofCIP orCIM. Wewillin-
clude studies with mixed populations of people with neurological
conditions if we are able to obtain the data for participants with
generalised weakness syndrome due to CIP or CIM.
Types of interventions
We will include all trials of CIM and CIP that compare any re-
habilitation intervention, such as physiotherapy or occupational
therapy,orboth,with anyotherinterventions forimprovingfunc-
tion and activity. Possible and typical interventions in this review
might be cycling, sit-to-stand training, walking and gait training,
and neuromuscular electrical stimulation to lower extremity mus-
cle groups.
We will include all studies of inpatient and outpatient physical
rehabilitation in the acute and chronic phase that compare two or
more interventions; for example, neuromuscular electrical stimu-
lation versus usual therapy, or neuromuscular electrical stimula-
tion versus another active intervention (such as muscle strength
training, dressingexercises,orgaittraining). Theintervention and
control group must have received the same (standard) medication
or rehabilitation. We will therefore allow co-interventions as long
as they are provided in the same amount to all randomised partic-
ipants.
Types of outcome measures
The time frame for outcome measurement will be immediately
after the intervention and at follow-up one year later.
Primary outcomes
Ourprimaryoutcome measure willbeactivities (forexample,mo-
bility, walking, transfers, and self care), as measured by validated
outcome tools.
Measurement tools will be the Functional Independence Measure
(FIM) (Dodds 1993), the Barthel Index (Mahoney 1965) and
other validated scales for the ICU such as the Functional Status
Score for ICU (FSS-ICU) (Zanni 2010), the Acute Care Index
of Function (ACIF) (Roach 1988), the Physical Function Out-
come Measure (PFIT) (Skinner 2009), or other validated mea-
sures. Measures of walking ability will be gait speed in m/s and
six-minute walking distance (Norton-Craft 2012).
If studies use multiple scales to measure our primary outcome, we
will, in the absence of our preferred measures, list and report all
scales and measures used in these studies.
Secondary outcomes
We will report the following secondary outcomes.
1. Muscle strength (as measured by, for example, the Medical
Research Council (MRC) Scale for Muscle Strength (Fan 2012)).
2. Quality of life measured by validated measures, such as the
Short Form-36 Health Survey (SF-36) (Skinner 2011), the
RAND-36 (Kaarlola 2006), or the Assessment of Quality of Life
(AQol) Utility Instrument (Denehy 2008).
3. Frequency of adverse effects as a result of the intervention.
We will also report all serious adverse events, deﬁned as those
events that are life-threatening, require prolonged hospitalisation,
or are fatal. We will report adverse events that occur during the
intervention or at less than 12 months after study onset.
We will report any information on costs in the ’Discussion’.
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We will use GRADEpro (GRADEpro 2008) software and create
a ’Summary of ﬁndings’ table with the following outcomes: ac-
tivities, muscle strength, quality of life and adverse effects. Time
points for all outcomes in the ’Summary of ﬁndings’ table will be
immediately aftertheintervention andatfollow-up one yearlater.
We will use the ﬁve GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence (studies that con-
tribute data for the prespeciﬁed outcomes). We will use methods
and recommendations described in Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will justify all decisions to down- or up-grade the quality of
evidence using footnotes.
Search methods for identiﬁcation of studies
Electronic searches
We will search the Cochrane Neuromuscular Disease Group Spe-
cialized Register, CENTRAL (The Cochrane Library current is-
sue), MEDLINE (1966 to present), EMBASE (1980 to present),
CINAHL(from1982), andthePhysiotherapyEvidence Database
(PEDro, http://www.pedro.org.au/). We will use the search strat-
egy in Appendix 1 to search MEDLINE and will modify it for the
other databases. There will be no language restrictions.
We will search ClinicalTrials.gov (http://clinicaltrials.gov/),
the World Health Organization International Clinical Tri-
als Registry Platform (ICTRP) portal (http://www.who.int/
ictrp/en/) and the European Union Clinical Trials Register (
www.clinicaltrialsregister.eu) for ongoing trials and further data
about included studies.
Searching other resources
We will review the bibliographies of any identiﬁed RCTs and con-
tact the authors and known experts in the ﬁeld to identify addi-
tional published or unpublished data.
Data collection and analysis
Selection of studies
Two review authors (JM and MP) will independently select the
eligible trials based on the predeﬁned selection criteria and will
resolve disagreement through discussion with theother review au-
thors.Ifweneedfurtherinformation, wewillcontacttrialauthors.
Data extraction and management
Two review authors (MP and JM) will independently extract trial
and outcome data from the selected trials using a data collection
form. If one of the review authors was involved in an included
trial, another review author will extract trial and outcome data
from this trial.
Thereviewauthorswillextractthefollowingdata(accordingtothe
Cochrane Handbook for Systematic Reviews of Interventions Table
7.3.a):
1. source;
2. eligibility;
3. participants (important imbalances in prognostic factors at
baseline, country, number of participants, age, gender, inclusion
and exclusion criteria, educational background, socioeconomic
status, cognition, pre-existing neurological impairment(s),
neurological history);
4. interventions;
5. outcomes and their time point of measurement;
6. comparison (details of interventions in treatment and
control groups, duration of treatment, details of co-intervention
in the groups;
7. results;
8. funding source and conﬂicts of interest among
investigators; and
9. miscellaneous.
Two review authors (MP and JM) will check the extracted data
for agreement. If they are not able to reach a consensus, a third
review author will arbitrate.
If necessary, the review authors will contact trial authors for more
information. We will reportthe outcome of effortsto source miss-
ing data in the review.
Onereviewauthor (JM) will enterdatainto theCochrane author-
ingandstatisticalsoftwareReviewManager5(RevMan) (RevMan
2012), and a second author (MP) will check the data entry.
Assessment of risk of bias in included studies
Two review authors (JK, MP) will independently assess the risk of
bias in the included trials according to the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a).
We will use checklists to independently assess:
• methods of random sequence generation;
• methods of allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessors;
• incomplete outcome data (dropouts, use of an intention-to-
treat analysis (ITT));
• selective outcome reporting; and
• other sources of bias.
Our judgements will be “High risk of bias”, “Low risk of bias” or
“Unclear risk of bias”. We will use “Unclear” where there is too
little information, or when what happened in the study is known
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between authors during the ’Risk of bias’ assessment, and we will
resolve disagreement by reaching consensus through discussion.
We will contact trialists for clariﬁcation and to request missing
information when necessary.
Measures of treatment effect
Foralloutcomesrepresentingcontinuousdata,wewillentermeans
and standard deviations. We will calculate a pooled estimate of
the mean difference (MD) with 95% conﬁdence intervals (CI).
If studies assess the same outcome but measure it with different
scales, we will calculate standardised mean differences (SMD) in-
stead of MD (Higgins 2011b). For all binary outcomes, we will
calculate risk ratios (RR) with 95% CI. Where trials (or groups
within a trial) have no event, e.g. no adverse events, we will cal-
culate risk differences (RD) with 95% CI instead of RR. For all
statistical comparisons we will use RevMan.
Unit of analysis issues
According to guidance in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011c), we will use only the ﬁrst
period of cross-over trials and analyse the data as a parallel group
trial.
Dealing with missing data
We will contact the relevant principal investigators in order to
retrieve missing data. We will report the results of these efforts in
the review.
Assessment of heterogeneity
We will use the Higgins and Thompson’s I2 statistic in order to
assess heterogeneity (Higgins 2002). The I2 statistic ranges from
0% to 100%, where 0% indicates that the size of effects, for ex-
ample MDs of different studies pooled, are consistent with each
other.
If we detect heterogeneity, we will attempt to explore the reasons
forit(forexample,whetherrelatedtocharacteristicsofthestudies,
such as participants, risk of bias, year of study, or place of study).
Assessment of reporting biases
Wewill assesspublication bias visually using RevMan funnel plots
if the review includes 10 or more studies. However, publication
bias is not the only cause of asymmetrical funnel plots.
Data synthesis
We will use a random-effects model, regardless of the level of het-
erogeneityfoundwiththeI2 statistic.Thus,incasesofheterogene-
ity, we will not violate the preconditions of a ﬁxed-effect model
approach.
If the review includes more than one comparison, which cannot
be included inthesame analysis, we willreporttheresultsfor each
comparison separately.
Subgroup analysis and investigation of heterogeneity
We will conduct three subgroup analyses as follows.
1. Duration of illness or critical condition: acute/subacute phase
(ﬁrst six months of initiated intervention) versus chronic phase
(illness of more than six months’ duration and interventions ini-
tiated accordingly).
2. Use of deﬁnitions of CIP and CIM: use of deﬁnitive deﬁnition
of CIP and CIM in studies versus use of probable deﬁnition.
3.Imbalanceofprognosticfactorsatbaseline(suchasage,duration
of illness and duration of ventilation).
Wewillconsidermeta-regressionasanextensiontosubgroupanal-
yses when there are more than 10 studies in a meta-analysis.
Sensitivity analysis
To test the robustness of results we will conduct a sensitivity anal-
ysis, removing studies at high or unclear risk of bias (for example,
high or unclear versus low risk of bias from method of randomi-
sation).
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A P P E N D I C E S
Appendix 1. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to June Week 4 2013>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (378039)
2 controlled clinical trial.pt. (88553)
3 randomized.ab. (275457)
4 placebo.ab. (149266)
5 drug therapy.fs. (1722456)
6 randomly.ab. (193185)
7 trial.ab. (287286)
8 groups.ab. (1239381)
9 or/1-8 (3208243)
10 exp animals/ not humans.sh. (3996981)
11 9 not 10 (2730505)
12 Polyneuropathies/ (4193)
13 Muscle Weakness/ (5472)
14 Rhabdomyolysis/ (4264)
15 Quadriplegia/ (6952)
16 Paresis/ (4918)
17 neuromuscular manifestation$1.tw. (88)
18 (polyneuropath$ or myopath$).tw. (28621)
19 polyneuromyopath$.tw. (38)
20 neuromuscular disorder$.tw. (3081)
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22 paresis.tw. (7490)
23 quadriplegia.tw. (2112)
24 weakness.tw. (33892)
25 neuromyopath$.tw. (344)
26 motor syndrome.tw. (172)
27 muscle function.tw. (6982)
28 muscle strength/ (8259)
29 (muscle strength or respiratory failure).tw. (29931)
30 or/12-29 (127024)
31 Intensive Care/ (14924)
32 Critical Illness/ (16281)
33 intensive care.tw. (81047)
34 critical$ ill$.tw. (27308)
35 ventilator weaning/ (2849)
36 respiration, artiﬁcial/ (38024)
37 or/31-36 (138468)
38 electric stimulation therapy/ or electrostimulation.mp. or (electric$ adj2 stimulation).tw. (59228)
39 ((leg or lower) adj2 (limb$ or extremit$)).tw. (60715)
40 38 and 39 (873)
41 exp Exercise/ (109120)
42 physical therapy modalities/ or physiotherap$.tw. or physical therap$.tw. (42309)
43 exp Exercise Therapy/ (29085)
44 Musculoskeletal Manipulations/ (893)
45 Occupational Therapy/ (9889)
46 recovery of function/ (30425)
47 “Activities of Daily Living”/ (49818)
48 strength training.mp. (2517)
49 muscle training.mp. (1264)
50 (physical adj5 rehabilitation).tw. (4999)
51 or/40-50 (251838)
52 11 and 30 and 37 and 51 (85)
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the conception and design of the protocol and approved the protocol. All authors will be involved in all
stages of the review. JM will screen titles and abstracts of publications identiﬁed by the searches. MP and JM will extract trial and
outcome data from the selected trials and analyse outcome data. JK and MP will assess the risk of bias in included studies. All authors
will interpret the results.
D E C L A R A T I O N S O F I N T E R E S T
None known
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Internal sources
• Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria in Kreischa GmbH, An
derWolfsschlucht 1-2, 01731 Kreischa, Germany.
• Lehrstuhl Therapiewissenschaften, SRH Fachhochschule für Gesundheit Gera gGmbH, Hermann-Drechsler-Str. 2, 07548
Gera, Germany.
• Gesundheitswissenschaften/Public Health, Medizinische Fakultät Carl Gustav Carus der TU Dresden, Fetscherstr. 74, 01307
Dresden, Germany.
• University of Southampton, UK.
External sources
• No sources of support supplied
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